5.69
+2.52%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Harbin Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 600664.SS. It has been listed since 29 June 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥15.96bn and net income of CN¥361.6m. At that date it held total assets of CN¥14.29bn and shareholders' equity of CN¥5.69bn.
Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, wholesale and retail of pharmaceutical products. The company is headquartered in Harbin, Heilongjiang. The firm's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Company’s main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Jun 1993
- Employees
- 10,064
- Website
- hayao.com ↗
Leadership
Pay as last reported
- Ms. Xiaoping HuChairman of the Board, since 2021
- Mr. Chuanyou LuPresident, Director, since 2021CN¥1.4m
- Mr. Bo LiuFinance Director, Vice President, since 2008CN¥1.2m
- Mr. Xiaodong MengVice President, Secretary of the BoardCN¥1.1m
- Mr. Guangjun DiaoVice President
- Mr. Haitao JiangVice PresidentCN¥982,500
- Mr. Bangdong LiVice PresidentCN¥752,500
- Mr. Jicheng XiaVice PresidentCN¥756,200
- Mr. Mo LiuDirector
- Mr. Zhifeng SunDirector
- Mr. Shiwei YinDirector
- Ms. Ying LeiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Harbin Pharmaceutical Group employs 10,064 full-time employees in Heilongjiang.
- The company focuses on innovative R&D in antibiotics, modern Chinese medicine, and biopharmaceuticals.
- Harbin Pharmaceutical Group offers a diverse product portfolio including calcium gluconate and amoxicillin capsules.
Weaknesses
- Harbin Pharmaceutical Group's headquarters is located in Harbin, Heilongjiang, a less prominent city for pharmaceuticals.
- The company's business is limited to the Chinese market without international expansion mentioned.
- Harbin Pharmaceutical Group's product range lacks specific high-demand global pharmaceuticals.
Opportunities
- The growing Chinese pharmaceutical market presents opportunities for Harbin Pharmaceutical Group's innovative R&D.
- Expanding into international markets could leverage Harbin Pharmaceutical Group's biopharmaceutical expertise.
- Increasing demand for traditional Chinese medicine products aligns with Harbin Pharmaceutical Group's focus.
Threats
- Competition from larger Chinese pharmaceutical companies poses a threat to Harbin Pharmaceutical Group.
- Regulatory changes in China's pharmaceutical sector could impact Harbin Pharmaceutical Group's operations.
- Economic downturns in China may reduce consumer spending on health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.